Gastroesophageal Junction Carcinoma Clinical Trials

6 recruiting

Gastroesophageal Junction Carcinoma Trials at a Glance

6 actively recruiting trials for gastroesophageal junction carcinoma are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Dallas, Cincinnati, and Ann Arbor. Lead sponsors running gastroesophageal junction carcinoma studies include I-Mab Biopharma US Limited, Alliance for Clinical Trials in Oncology, and Guardant Health, Inc..

Browse gastroesophageal junction carcinoma trials by phase

Treatments under study

About Gastroesophageal Junction Carcinoma Clinical Trials

Looking for clinical trials for Gastroesophageal Junction Carcinoma? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastroesophageal Junction Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastroesophageal Junction Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Not Applicable

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

Esophageal CarcinomaGastric CarcinomaGastroesophageal Junction Carcinoma+7 more
Alliance for Clinical Trials in Oncology420 enrolled287 locationsNCT07283939
Recruiting
Phase 1

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Gastric CancerEsophageal AdenocarcinomaMetastatic Cancer+5 more
I-Mab Biopharma US Limited330 enrolled21 locationsNCT04900818
Recruiting
Phase 2

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Gastric CancerEsophageal AdenocarcinomaMetastatic Cancer+3 more
I-Mab Biopharma US Limited180 enrolled3 locationsNCT07432295
Recruiting
Phase 2

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Breast CarcinomaUrothelial CarcinomaOvarian Carcinoma+26 more
Mayo Clinic27 enrolled1 locationNCT07285044
Recruiting
Phase 2

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Esophageal Squamous Cell CarcinomaEsophageal AdenocarcinomaGastroesophageal Junction Carcinoma
VA Office of Research and Development78 enrolled7 locationsNCT05563766
Recruiting

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Bladder CarcinomaEsophageal CarcinomaNon-small Cell Lung Cancer+13 more
Guardant Health, Inc.2,020 enrolled57 locationsNCT05059444